Zynerba Pharmaceuticals Announces Top Line Results from Pivotal CONNECT-FX Trial of Zygel™ (CBD Gel) in Fragile X Syndrome

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. SPCX
2. META
3. ABBV
4. SPY
5. FDX
6. IBM
7. MU
8. PFE
9. AWK
10. ACN

Go back to Zynerba Pharmaceuticals Announces Top Line Results from Pivotal CONNECT-FX Trial of Zygel™ (CBD Gel) in Fragile X Syndrome

UPDATE: Needham & Company Downgrades Zynerba Pharmaceuticals (ZYNE) to Hold

July 1, 2020 7:18 AM EDT

(Updated - July 1, 2020 7:22 AM EDT)

(updating comment)

Needham & Company analyst Serge Belanger downgraded Zynerba Pharmaceuticals (NASDAQ: ZYNE) from Buy to Hold.

The analyst comments "Zygel missed primary and secondary endpoints in the pivotal ph 3 CONNECT-FX trial, but met the... More